Setara Closes 90 Million Dollar Series A

Company Setara Biosciences; Jazz Pharmaceuticals (Actio asset) Event Type Series A financing Modality Oral small-molecule TRPV4 inhibitor Asset STAR-0871 (formerly ABS-0871) Target TRPV4 Disease Area Charcot-Marie-Tooth type 2C; overactive bladder Summary Setara Biosciences announced on 30 October that it completed a $90 million Series A…